The development of ADCs is not a one-size-fits-all approach. In fact, a number of diverse factors impact the properties of an ADC including; payload, drug-to-antibody ratio, site of conjugation, and homogeneity. For each target antigen, there is an optimal combination of these factors. Our novel and highly differentiated platforms allow us to optimize these properties for a given target and develop ADCs that best address patient needs.
Traditional ADCs are a class of cancer biotherapeutics that combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drug payloads. Antibodies and payloads are chemically linked, allowing specific drug delivery to cancer cells targeted by the antibody. After ADCs enter a cell, the conjugated payload is released and kills the cell. While ADCs are intended to target and kill tumor cells while leaving healthy cells unharmed, first-generation ADC platforms had several limitations that resulted in ADCs with narrow therapeutic windows and unacceptable toxicities for patients. Our ADC platforms incorporate additional features to minimize off-target toxicity and increase efficacy. In addition, our ADC platforms are able to go beyond cytotoxic payloads and have the capability to deliver immunostimulatory payloads enabling novel first-in-class treatments for more people living with cancer.